Gilbert Z. Murimwa

Gilbert Z. Murimwa

Auto-generated profile, based on publicly available information

Gilbert Z. Murimwa

Department of Surgery UT Southwestern Medical Center Dallas Texas USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
DGDebolina Ganguly
Debolina Ganguly
MSMarcel Oliver Schmidt
Marcel Oliver Schmidt
MCMorgan Coleman
Morgan Coleman
TNTuong-Vi Cindy Ngo
Tuong-Vi Cindy Ngo
NSNoah Sorrelle
Noah Sorrelle
Rolf BrekkenRolf Brekken
Rolf Brekken
Metastatic cancer cells adapt to thrive in secondary organs. To investigate metastatic adaptation, we performed transcriptomic analysis of metastatic and non-metastatic murine breast cancer cells. We found that pleiotrophin (PTN), a neurotrophic cytokine, is a metastasis-associated factor that is expressed highly by aggressive breast cancers. Moreover, elevated PTN in plasma correlated significantly with metastasis and reduced survival of breast cancer patients. Mechanistically, we find that PTN activates NF-κB in cancer cells leading to altered cytokine production, subsequent neutrophil recruitment, and an immune suppressive microenvironment. Consequently, inhibition of PTN, pharmacologically or genetically, reduces the accumulation of tumor-associated neutrophils and reverts local immune suppression, resulting in increased T cell activation and attenuated metastasis. Furthermore, inhibition of PTN significantly enhanced the efficacy of immune checkpoint blockade and chemotherapy in reducing metastatic burden in mice. These findings establish PTN as a previously unrecognized driver of a prometastatic immune niche and thus represents a promising therapeutic target for the treatment of metastatic breast cancer.

27 May 2023 in Journal of Surgical Oncology
Verified
Journal Article
Open access
GMGilbert Z. Murimwa
Gilbert Z. Murimwa
JKJohn Karalis
John Karalis
JMJennie Meier
Jennie Meier
MNMithin Nehrubabu
Mithin Nehrubabu
MTMicah Thornton
Micah Thornton
PPPatricio M. Polanco
Patricio M. Polanco
Introduction: Curative intent for localized pancreatic cancer (pancreatic ductal adenocarcinoma [PDAC]) requires surgery, but despite improved perioperative outcomes, surgery remains underutilized. This study analyzed the Texas Cancer Registry (TCR) to identify resectable PDAC patients who underwent curative‐intent surgery in Texas between 2004 and 2018. We then evaluated demographic and clinical factors associated with failure to operate and survival (OS).Methods: We identified patients with localized PDAC or regional lymph node spread between 2004 and 2018 in the TCR. Resection rates were determined and multivariable regression and cox proportional hazards were used to identify factors associated with failure to OS.Results: Of 4274 patients, 22% underwent resection, 57% were not offered surgery, 6% had comorbidities precluding surgery, and 3% refused. Resection rates decreased from 31% in 2004 to 22% in 2018. Increasing age was associated with failure to operate (odds ratio [OR] 2.55; 95% confidence interval [CI] 1.80–3.61; p < 0.0001) while treatment at a Commission on Cancer (CoC) center correlated with reduced failure to operate (OR 0.63; 95% CI 0.50–0.78; p < 0.0001). Resection correlated with survival (HR 0.34; 95% CI 0.31‐0.38; p < 0.0001) as did treatment at a National Cancer Institute (NCI)‐designated center (hazard ratio 0.79; 95% CI 0.70–0.89; p < 0.0001).Conclusions: Surgery is underutilized for the treatment of resectable PDAC in Texas with decreasing utilization, annually. Evaluation at CoC was associated with improved resection rates and NCI was associated with increased survival. Expanding access to multidisciplinary care including trained hepato‐pancreatico‐biliary surgeons may improve outcomes for PDAC patients.

29 May 2025 in Cancer Research
Verified
Journal Article
Open access
GMGilbert Z. Murimwa
Gilbert Z. Murimwa
NWNatalie E. Williams
Natalie E. Williams
DADina Alzhanova
Dina Alzhanova
AMAmir Mohammadi
Amir Mohammadi
JWJill M. Westcott
Jill M. Westcott
Rolf BrekkenRolf Brekken
Rolf Brekken
The 5-year overall survival rate for pancreatic cancer remains ∼13%, underscoring the urgent need for improved treatment strategies. TGFβ is a promising target due to its significant involvement in the desmoplasia, immune suppression, and chemoresistance characteristics of pancreatic cancer. More than 300 clinical trials targeting TGFβ have been conducted in unselected patient cohorts; however, none of the therapies have gained FDA approval. Nevertheless, TGFβ blockade may hold promise for a subset of cancers with nonfunctional TGFβ signaling. More than 25% of pancreatic cancers carry mutations in SMAD4, a key component of canonical TGFβ signaling. In this study, we investigated the potential for stratifying patients based on SMAD4 mutational status to identify tumors susceptible to TGFβ inhibition. Analysis of SMAD4 expression in human pancreatic tumors revealed that SMAD4 mutation or loss is associated with worse disease-free survival. Intriguingly, intratumoral SMAD4 expression displayed heterogeneity among human pancreatic cancer samples. SMAD4-deficient genetically engineered mouse models and orthotopic SMAD4 knockout tumor models exhibited reduced survival, increased metastasis, and alterations in the tumor microenvironment compared with SMAD4 wild-type controls, consistent with gene and protein expression changes in the absence of functional SMAD4. Importantly, treating mice bearing SMAD4-deficient tumors with a blocking TGFβ antibody reduced tumor weight and improved survival. These findings suggest that genomic stratification by TGFβ axis alterations, such as SMAD4 mutations, may be a promising approach to identifying patients likely to benefit from a TGFβ inhibitor. Significance: Targeting TGFβ in pancreatic cancers that are deficient in canonical TGFβ signaling could provide a therapeutic strategy to enhance standard and immune therapy approaches for a substantial population of pancreatic cancer patients.

8 June 2023 in The American Journal of Surgery
Verified
Journal Article
Closed access
GMGilbert Z. Murimwa
Gilbert Z. Murimwa
JMJennie Meier
Jennie Meier
MNMithin Nehrubabu
Mithin Nehrubabu
HZHerbert J. Zeh
Herbert J. Zeh
AYAdam C. Yopp
Adam C. Yopp
PPPatricio M. Polanco
Patricio M. Polanco

15 November 2022 in Cancer Research
Verified
Journal Article
Open access
HHHuocong Huang
Huocong Huang
ZWZhaoning Wang
Zhaoning Wang
YZYuqing Zhang
Yuqing Zhang
RPRachana N. Pradhan
Rachana N. Pradhan
DGDebolina Ganguly
Debolina Ganguly
Rolf BrekkenRolf Brekken
Rolf Brekken
Recent studies have identified a unique cancer-associated fibroblast (CAF) population termed antigen-presenting CAFs (apCAFs), characterized by the expression of major histocompatibility complex class II molecules, suggesting a function in regulating tumor immunity. Here, by integrating multiple single-cell RNA-sequencing studies and performing robust lineage-tracing assays, we find that apCAFs are derived from mesothelial cells. During pancreatic cancer progression, mesothelial cells form apCAFs by downregulating mesothelial features and gaining fibroblastic features, a process induced by interleukin-1 and transforming growth factor β. apCAFs directly ligate and induce naive CD4+ T cells into regulatory T cells (Tregs) in an antigen-specific manner. Moreover, treatment with an antibody targeting the mesothelial cell marker mesothelin can effectively inhibit mesothelial cell to apCAF transition and Treg formation induced by apCAFs. Taken together, our study elucidates how mesothelial cells may contribute to immune evasion in pancreatic cancer and provides insight on strategies to enhance cancer immune therapy. Citation Format: Huocong Huang, Zhaoning Wang, Yuqing Zhang, Rachana N. Pradhan, Debolina Ganguly, Raghav Chandra, Gilbert Murimwa, Steven Wright, Xiaowu Gu, Ravikanth Maddipati, Sören Müller, Shannon J. Turley, Rolf A. Brekken. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr C078.

18 January 2026 in Cancer Medicine
Verified
Journal Article
Open access
MKMuhammad Sohaib Khan
Muhammad Sohaib Khan
TLTammy Leonard
Tammy Leonard
SYSean G. Young
Sean G. Young
NWNatalie Williams
Natalie Williams
JMJennie Meier
Jennie Meier
PPPatricio M. Polanco
Patricio M. Polanco
Background: Relationships between socioeconomic factors and metastatic cancer at diagnosis have not been well studied. Using CDC's Social Vulnerability Index (SVI) we studied the association of metastatic cancer at initial diagnosis with 16 social factors and their interaction with insurance status. Methods: California and Texas cancer registries, merged with the SVI database, were used to identify adult patients diagnosed with breast, colorectal, liver, lung, ovarian, pancreatic, or prostate cancer from 2015 to 2019. To determine the association of SVI with metastatic cancer at initial diagnosis, multivariable binary logistic regression analyses were performed. Results: Of the 654,016 patients included, 149,476 (21.5%) were diagnosed with metastatic cancer at diagnosis. Overall, the adjusted odds of metastasis at diagnosis increased by 5% for every 10 unit increase in SVI. Stratified by cancer type, the odds (95% confidence interval) of metastatic cancer at diagnosis were: breast 1.04 (1.03–1.05), colorectal 1.01 (1.01–1.02), liver 1.03 (1.02–1.05), lung 1.01 (1.01–1.02), pancreatic 1.02 (1.01–1.03), prostate 1.06 (1.05–1.07). Interaction analysis of insurance with SVI revealed that the marginal effect of the association between SVI and the risk of metastasis at initial diagnosis increased most substantially as SVI increased for patients who had insurance. It was relatively constant for uninsured and Medicaid patients, who had the overall highest average risk. Conclusions: Increased neighborhood social vulnerability is associated with an increased risk of metastatic cancer at initial diagnosis. While uninsured patients or those on Medicaid had a higher risk, patients with other insurance types experienced the largest increases in risk associated with increasing SVI.